JCR Pharmaceuticals Co., Ltd. (TSE: 4552)
Health Care · Pharmaceuticals · JP
¥529.00
+9.52% today · -18.2% 1Y
JCR Pharmaceuticals Co., Ltd. (TSE: 4552) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $407.69M and employs 985 people.
Over the last twelve months the share price has lost 18.2%, trading between 444.00 and 824.00.
Tweenvest scores JCR Pharmaceuticals Co., Ltd. across four factors: quality 61/100, value 39/100, growth 76/100, dividend 81/100. Its strongest factor is dividend.
4552 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $407.69M
- Revenue (TTM)
- $255.01M
- P/E
- 78.98
- EPS
- 6.70
- Dividend yield
- 4.14%
- Beta (5Y)
- 0.18
- 52-week high
- ¥824.00
- 52-week low
- ¥444.00
- Avg volume (3M)
- —
- Shares outstanding
- 122.03M
- Employees
- 985
- Next earnings
- —
About JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. is a specialized pharmaceutical firm primarily engaged in the creation, development, manufacturing, international trade, and distribution of medicinal products, regenerative therapies, and active pharmaceutical ingredients within Japan. The company offers a range of therapeutic solutions, including GROWJECT, which addresses growth hormone deficiency and short stature; IZCARGO, prescribed for Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion, utilized in the management of Fabry disease; and TEMCELL HS Inj, employed to treat acute graft-versus-host disease. Beyond its current offerings, JCR Pharmaceuticals is also developing Epoetin Alfa BS and Darbepoetin Alfa BS Injections, both intended for the treatment of renal anemia. Furthermore, the company markets various medical devices and laboratory instruments. Founded in 1975, its headquarters are situated in Ashiya, Japan.
- ISIN
- JP3701000006
- Founded
- 1975
- Listed since
- Nov 17, 2005
- Exchange
- The Tokyo Stock Exchange
- Currency
- JPY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Renata PLCDSE: RENATA | $418.98M | Tk449.90 | +0.27% |
| Hangzhou TianMuShan Pharmaceutical Enterprise Co.,LtdSHSE: 600671 | $416.71M | CN¥22.92 | +5.19% |
| Chengdu huasun technology group Inc. , LTD.SZSE: 000790 | $413.45M | CN¥4.44 | +0.45% |
| Atea Pharmaceuticals, Inc.NasdaqGS: AVIR | $413.05M | $5.09 | -1.17% |
| Allergy Therapeutics plcAIM: AGY | $398.04M | £0.05 | 0.00% |
| Shandong Sito Bio-technology Co., Ltd.SZSE: 300583 | $394.52M | CN¥13.93 | +1.68% |
| Aarti Drugs LimitedBSE: 524348 | $389.58M | Rs413.10 | -2.12% |
| Foresee Pharmaceuticals Co., Ltd.TPEX: 6576 | $385.29M | NT$78.20 | -1.01% |
Figures last refreshed Oct 11, 2026.